David Southwell: CEO of Volastra Therapeutics
David Southwell, CEO of Volastra Therapeutics, shares his insights about leadership in biopharma and how Volastra is working to discover and develop oncology therapeutics targeting chromosomal instability, a vulnerability of cancers.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.